<div id="readability-page-1"><div>Barinthus Biotherapeutics Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick &amp; Foti, LLC (“KSF”) are investigating the proposed merger of Barinthus Biotherapeutics plc (the “Company”) (NasdaqGM: BRNS) and Clywedog Therapeutics, Inc. Upon consummation of the transaction, Barinthus shareholders will own only 34.33% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Barinthus shareholders. If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgm-brns/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com. CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn <img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA1MTE3NTUyNDdyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA1MTE3NTUyNDdyMQ"/> Kahn Swick &amp; Foti, LLC Lewis Kahn, Managing Partner lewis.kahn@ksfcounsel.com 855-768-1857 1100 Poydras St., Suite 960 New Orleans, LA 70163 View source version on businesswire.com: https://www.businesswire.com/news/home/20260511755247/en/</div></div>

BRNS

納斯達克生物科技指數 ETF - iShares Nasdaq

醫藥突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

標普生物技術 3 倍做多 - Direxion

2 倍做多納斯達克生物技術 ETF - ProShares

動態生物技術與基因組 ETF - Invesco

標普生物技術 ETF - SPDR

IBBQ

紐交所高增長板生物技術指數 ETF - First Trust

Kahn Swick & Foti, LLC 正在調查 Barinthus Biotherapeutics plc（納斯達克代碼：BRNS）與 Clywedog Therapeutics, Inc. 之間的擬議合併。合併後，Barinthus 的股東將僅持有新實體的 34.33%。該公司旨在評估合併過程對 Barinthus 股東的公平性和充分性。感興趣的各方可以聯繫 KSF 管理合夥人 Lewis S. Kahn，獲取有關與該交易相關的法律權利的更多信息

Barinthus Biotherapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS

MorningStar

Barinthus Biotherapeutics

Invesco Nasdaq Biotechnology ETF

Barinthus Biotherapeutics 投資者警報：Kahn Swick & Foti, LLC 正在調查 Barinthus Biotherapeutics plc 的合併 - BRNS